510(k) device
eRapid with eTrack System
Pari Respiratory Equipment, Inc. · Nebulizer (Direct Patient Interface) (CAF, Class II) · First FDA decision May 30, 2012, newest Dec 19, 2025AsthmaCOPD and emphysema
Last checked: Nov 19, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
3
510(k) pathway
Device trials
2
Naming "eRapid"
MAUDE reports
2
Brand "eRapid", since 2015
PubMed studies
18
Mentioning "eRapid"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing eRapid with eTrack System
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 3 of 3 decisions filed under this name.
K251572 · Decided Dec 19, 2025 · 211 days after receipt
Device type: Nebulizer (Direct Patient Interface) (CAF) · Anesthesiology & Respiratory
- eRapid Nebulizer System510(k)
K223840 · Decided Aug 11, 2023 · 232 days after receipt
Device type: Nebulizer (Direct Patient Interface) (CAF) · Anesthesiology & Respiratory
- ERAPID NEBULIZER SYSTEM510(k)
K112859 · Decided May 30, 2012 · 243 days after receipt
Device type: Nebulizer (Direct Patient Interface) (CAF) · Anesthesiology & Respiratory
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
- NebulizersLocal determinationIn effectL33370CGS Administrators, LLCUpdated Feb 12, 2026
- NebulizersProposed local determinationProposedDL33370CGS Administrators, LLCUpdated Aug 22, 2025
Clinical trials
Device studies on ClinicalTrials.gov that name "eRapid", any status and sponsor, newest update first.
- Development and Testing of a TTDSS for Cancer PatientsStatus unknown
St. Martin De Porress HospitalAcademic, hospital or other
NCT05446051 · 136 participants (planned) · Start Jul 25, 2022 · Primary completion Nov 6, 2023
Device: the Mandarin Version of the electronic patient self-Reporting of Adverse-events (eRAPID-MV); the telephone triage decision support system (TTDSS) · For: Treatment Side Effects
Sites: Chiayi City, Taiwan
- eRAPID Feasibility Pilot Study in Pelvic RadiotherapyPivotal-lookingCompleted
University of LeedsAcademic, hospital or other
NCT02747264 · 167 participants · Start Dec 1, 2016 · Primary completion Jun 1, 2018
Device: eRAPID · For: Cancer
Sites: Manchester, United Kingdom; Leeds, United Kingdom
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "eRapid", and for the whole product code for context.
This brand
2 reports: 1 malfunction, 1 injury, 0 death
Whole product code CAF
2,410 reports: 2,117 malfunction, 199 injury, 27 death
Newest reports for this brand
- ERAPIDInjury
PARI RESPIRATORY EQUIPMENT, INC.
MW5093856 · Received Mar 19, 2020 · Event dated Feb 1, 2020
Device type: Nebulizer (Direct Patient Interface) (CAF)
Device problem as coded: Break
Patient problem as coded: No Information
- ERAPID NEBULIZER HANDSETMalfunction
PARI RESPIRATORY EQUIPMENT INC.
MW5088273 · Received Jul 19, 2019 · Event dated Jul 11, 2019
Device type: Nebulizer (Direct Patient Interface) (CAF)
Device problem as coded: Corroded
Patient problem as coded: No Known Impact Or Consequence To Patient
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recall in FDA's data is linked to these FDA numbers.
Published research
The most relevant PubMed records for "eRapid"[tiab]. The summary above synthesizes these.
- Phase III Randomized Controlled Trial of eRAPID: eHealth Intervention During Chemotherapy.
Absolom K, Warrington L, Hudson E, et al. · J Clin Oncol · 2021Clinical Trial, Phase III, Randomized Controlled Trial
- Cost-Effectiveness of eRAPID eHealth Intervention for Symptom Management During Chemotherapy.
Dawkins B, Absolom K, Hewison J, et al. · JCO Oncol Pract · 2024Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- ERAPID: an endߛtoߛend RNAߛseq analysis pipeline for integrative candidate biomarker discovery with applications to neuropsychiatric disorders.
Park J, Youn S, Kang K, et al. · Methods · 2026Research Support, Non-U.S. Gov't
- Online Symptom Monitoring During Pelvic Radiation Therapy: Randomized Pilot Trial of the eRAPID Intervention.
Holch P, Absolom KL, Henry AM, et al. · Int J Radiat Oncol Biol Phys · 2023Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Online symptom monitoring for lung cancer patients receiving systemic therapy: a feasibility implementation project.
Reddy S, Gibson A, Peacock R, et al. · J Thorac Dis · 2026
- Development of an integrated electronic platform for patient self-report and management of adverse events during cancer treatment.
Holch P, Warrington L, Bamforth LCA, et al. · Ann Oncol · 2017
- Online tool for monitoring adverse events in patients with cancer during treatment (eRAPID): field testing in a clinical setting.
Warrington L, Absolom K, Holch P, et al. · BMJ Open · 2019Observational Study, Research Support, Non-U.S. Gov't
- Patient and clinician perspectives of an eHealth intervention for supporting cancer treatment in the UK: mixed methods evaluation of the eRAPID randomised controlled trial.
Warrington L, Holmes M, Gibson A, et al. · BMJ Open · 2024Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- eRAPID electronic patient self-Reporting of Adverse-events: Patient Information and aDvice: a pilot study protocol in pelvic radiotherapy.
Holch P, Pini S, Henry AM, et al. · Pilot Feasibility Stud · 2018
- Engaging Patients and Clinicians in Online Reporting of Adverse Effects During Chemotherapy for Cancer: The eRAPID System (Electronic Patient Self-Reporting of Adverse Events: Patient Information and aDvice).
Absolom K, Gibson A, Velikova G · Med Care · 2019Research Support, Non-U.S. Gov't
- Randomized trial of efficacy and safety of dornase alfa delivered by eRapid nebulizer in cystic fibrosis patients.
Sawicki GS, Chou W, Raimundo K, et al. · J Cyst Fibros · 2015Multicenter Study, Randomized Controlled Trial
- Patient experiences of an electronic PRO tailored feedback system for symptom management following upper gastrointestinal cancer surgery.
Richards HS, Portal A, Absolom K, et al. · Qual Life Res · 2021
Other devices of this type
Also filed under product code CAF.
- Propeller Sensor for SymbicortReciprocal Labs Corporation · 510(k) 2020
- Hailie Sensor NF0110Adherium (Nz), Ltd. · 510(k) 2023
- Ultrasonic Mesh NebulizerFoshan Gaunying Electronics Co., Ltd. · 510(k) 2014
- Portable NebulizerMicrobase Technology Corporation · 510(k) 2018
- SmartTouchAdherium (Nz), Ltd. · 510(k) 2018
- Comp A-I-ROmron Healthcare, Inc. · 510(k) 2014
- Ultrasonic Nebulizer (Mesh Type)K-Jump Health Co., Ltd. · 510(k) 2013
- Hsiner Nebulizer Bottle, Cpr Masks and Face ShieldsHsiner Co., Ltd. · 510(k) 2008
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.